UA70960C2 - 4-амінозаміщені-2-заміщені-1,2,3,4-тетрагідрохіноліни як інгібітори протеїну, який переносить холестериловий етер - Google Patents

4-амінозаміщені-2-заміщені-1,2,3,4-тетрагідрохіноліни як інгібітори протеїну, який переносить холестериловий етер

Info

Publication number
UA70960C2
UA70960C2 UA2001031791A UA01031791A UA70960C2 UA 70960 C2 UA70960 C2 UA 70960C2 UA 2001031791 A UA2001031791 A UA 2001031791A UA 01031791 A UA01031791 A UA 01031791A UA 70960 C2 UA70960 C2 UA 70960C2
Authority
UA
Ukraine
Prior art keywords
inhibitors
cholesterol
aminosubstituted
tetrahydroquinolines
protein
Prior art date
Application number
UA2001031791A
Other languages
English (en)
Russian (ru)
Inventor
Майкл Пол Денінно
Джордж Теттех Магнус-Ерайтей
Роджер Бенджамін Раггері
Роналд Туре Уестер
Original Assignee
Пфайзер Продактс Інк.
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Інк., Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Інк.
Publication of UA70960C2 publication Critical patent/UA70960C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Винахід стосується інгібіторів протеїну, що переносить холестериловий етер Формули (І), їх проліків або фармацевтично прийнятних солей згаданих сполук або згаданих проліків, фармацевтичних композицій, що місять такі інгібітори, і використання таких інгібіторів для підвищення рівнів деяких ліпідів в плазмі, включаючи ліпопротеїни високої щільності – холестерол, і зменшення рівнів деяких інших ліпідів в плазмі, таких як ЛНЩ-холестерол і тригліцеридів, і відповідно лікування захворювань, які загострюються при низьких рівнях ЛВЩ-холестеролу і/або високих рівнях ЛНЩ-холестеролу і тригліцеридів, таких як атеросклероз і кардіоваскулярні захворювання у деяких ссавців, включаючи людей. (I)
UA2001031791A 1998-09-17 1999-09-10 4-амінозаміщені-2-заміщені-1,2,3,4-тетрагідрохіноліни як інгібітори протеїну, який переносить холестериловий етер UA70960C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10092798P 1998-09-17 1998-09-17
PCT/IB1999/001534 WO2000017165A1 (en) 1998-09-17 1999-09-10 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors

Publications (1)

Publication Number Publication Date
UA70960C2 true UA70960C2 (uk) 2004-11-15

Family

ID=22282246

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001031791A UA70960C2 (uk) 1998-09-17 1999-09-10 4-амінозаміщені-2-заміщені-1,2,3,4-тетрагідрохіноліни як інгібітори протеїну, який переносить холестериловий етер

Country Status (50)

Country Link
US (2) US6140343A (uk)
EP (1) EP1114032B1 (uk)
JP (1) JP3561474B2 (uk)
KR (1) KR100422286B1 (uk)
CN (2) CN1318057A (uk)
AP (1) AP1345A (uk)
AR (1) AR030523A1 (uk)
AT (1) ATE268324T1 (uk)
AU (1) AU747715B2 (uk)
BG (1) BG65101B1 (uk)
BR (1) BR9913855A (uk)
CA (1) CA2344248C (uk)
CO (1) CO5290250A1 (uk)
CR (1) CR6306A (uk)
CU (1) CU23053A3 (uk)
CZ (1) CZ2001954A3 (uk)
DE (1) DE69917790T2 (uk)
DK (1) DK1114032T3 (uk)
DZ (1) DZ2891A1 (uk)
EA (1) EA005761B1 (uk)
EE (1) EE200100167A (uk)
ES (1) ES2221420T3 (uk)
GC (1) GC0000108A (uk)
GE (1) GEP20032973B (uk)
GT (1) GT199900147A (uk)
HK (1) HK1039938A1 (uk)
HR (1) HRP20010200B1 (uk)
HU (1) HUP0103512A3 (uk)
ID (1) ID27838A (uk)
IL (1) IL141388A0 (uk)
IS (1) IS2278B (uk)
MA (1) MA26689A1 (uk)
MY (1) MY121405A (uk)
NO (1) NO319781B1 (uk)
NZ (1) NZ509837A (uk)
OA (1) OA11651A (uk)
PA (1) PA8481201A1 (uk)
PE (1) PE20001054A1 (uk)
PL (1) PL198124B1 (uk)
PT (1) PT1114032E (uk)
SI (1) SI1114032T1 (uk)
SK (1) SK3532001A3 (uk)
SV (1) SV1999000150A (uk)
TN (1) TNSN99170A1 (uk)
TR (1) TR200100780T2 (uk)
TW (1) TW502022B (uk)
UA (1) UA70960C2 (uk)
WO (1) WO2000017165A1 (uk)
YU (1) YU18101A (uk)
ZA (1) ZA200101745B (uk)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
SE0101161D0 (sv) 2001-03-30 2001-03-30 Astrazeneca Ab New compounds
WO2002087556A2 (en) * 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
CA2445623A1 (en) * 2001-04-30 2002-11-07 Pfizer Products Inc. Methods for preparing cetp inhibitors
OA12619A (en) * 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
KR100759635B1 (ko) * 2001-06-22 2007-09-17 화이자 프로덕츠 인코포레이티드 비정질 약물의 흡착체의 약학 조성물
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
CN1596240A (zh) * 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
KR101018318B1 (ko) * 2001-12-21 2011-03-04 노보 노르디스크 에이/에스 Ｇｋ 활성제로서의 아미드 유도체
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
DE60320940D1 (de) * 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
BR0307332A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
CA2744893A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
AU2003269327A1 (en) * 2002-10-21 2004-05-04 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
JPWO2004052863A1 (ja) * 2002-12-06 2006-04-13 協和醗酵工業株式会社 抗炎症剤
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
EP1435356A1 (en) * 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists
WO2004072042A2 (en) * 2003-02-12 2004-08-26 Carex S.A. Quinoline derivative and their use for modulation of lxr activity
KR20080008440A (ko) * 2003-03-17 2008-01-23 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
BRPI0408442A (pt) * 2003-03-17 2006-04-04 Japan Tobacco Inc método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
JP2006521344A (ja) * 2003-03-28 2006-09-21 ファイザー・プロダクツ・インク アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
SG141430A1 (en) 2003-05-30 2008-04-28 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
JP2007501218A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
KR20070087197A (ko) 2003-09-26 2007-08-27 니뽄 다바코 산교 가부시키가이샤 잔여 리포프로테인 생산 저해 방법
WO2005033082A2 (en) * 2003-09-30 2005-04-14 Pfizer Products Inc. Cetp inhibitors and metabolites thereof
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
US7390504B2 (en) * 2003-11-07 2008-06-24 Jj Pharma, Inc. HDL-boosting combination therapy complexes
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
PT1725234E (pt) 2004-03-05 2013-03-04 Univ Pennsylvania Métodos com efeitos secundários reduzidos para tratamento de patologias ou doenças associadas a hiperlipidemia e hipercolesterolemia
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
UA90269C2 (uk) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагідрохінолінові похідні і спосіб їх одержання
MY139887A (en) * 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
US20050282812A1 (en) * 2004-06-18 2005-12-22 JONES Zachary Inhibitors of cholesteryl ester transfer protein
KR100859223B1 (ko) * 2004-06-24 2008-09-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
US20080269284A1 (en) * 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
JP2008510835A (ja) * 2004-08-25 2008-04-10 エッセンシャリス，インク． カリウムａｔｐチャンネル開放因子の製剤処方、及びその使用
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US20070149567A1 (en) * 2004-09-23 2007-06-28 Pfizer Inc Quinoline compounds
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
MX2007007919A (es) 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
BRPI0608553A2 (pt) 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
AU2006265975B2 (en) * 2005-07-01 2011-12-15 Merck Sharp & Dohme Corp. Process for synthesizing a CETP inhibitor
JP2009500377A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
JP2009500378A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
JP4960355B2 (ja) * 2005-07-14 2012-06-27 ノボ・ノルデイスク・エー／エス ウレア型グルコキナーゼ活性化剤
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP4531027B2 (ja) * 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
BRPI0618379A2 (pt) 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007081521A2 (en) 2006-01-05 2007-07-19 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
GB0615670D0 (en) * 2006-08-07 2006-09-13 Syngenta Participations Ag Chemical compounds
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US20100210633A1 (en) * 2006-10-12 2010-08-19 Epix Delaware, Inc. Carboxamide compounds and their use
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
JP2010513534A (ja) * 2006-12-21 2010-04-30 エージェリオン ファーマシューティカルズ， インコーポレイテッド Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
JP2010515701A (ja) * 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
AU2008204530B2 (en) * 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
CN101220021B (zh) * 2007-01-12 2010-12-08 上海医药工业研究院 4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
CA2683534C (en) 2007-04-13 2015-02-24 Kowa Company, Ltd. Novel pyrimidine compound having dibenzylamine structure and medicament comprising the same
CN101795691A (zh) * 2007-07-02 2010-08-04 伊森舍丽斯有限公司 钾atp通道开放剂的盐及其用途
PL2207775T3 (pl) 2007-11-05 2012-08-31 Novartis Ag Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
AU2008333272B2 (en) 2007-12-03 2012-03-29 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
AU2008335135A1 (en) 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
ES2459468T3 (es) 2009-05-15 2014-05-09 Novartis Ag Arilpiridinas como inhibidores de aldosterona sintasa
MX2011012199A (es) 2009-05-15 2011-12-08 Novartis Ag Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
PL2435409T3 (pl) 2009-05-28 2015-01-30 Novartis Ag Podstawione pochodne aminopropionowe jako inhibitory neprylizyny
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
EP2993169B1 (en) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2507234B1 (en) 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US9052326B2 (en) 2011-01-26 2015-06-09 Institut National De La Santé Et De La Recherche Médicale (Inserm) Method for assessing a subject's risk of having a cardiovascular disease
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
PH12013502619A1 (en) 2011-06-17 2014-02-17 Merck Sharp & Dohme Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
AR087451A1 (es) * 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
IN2014CN02290A (uk) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
MX347400B (es) 2012-06-29 2017-04-18 Univ Nac Autónoma De México Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
SG11201506018PA (en) 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
MX376135B (es) * 2014-08-28 2025-03-04 Newamsterdam Pharma B V Composicion farmaceutica y combinacion terapeutica que comprende un inhibidor de la proteina de transferencia de colesteril ester e inhibidores de hmg coa reductasa
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US12479808B2 (en) 2020-06-08 2025-11-25 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
BR112023000808A2 (pt) 2020-07-29 2023-02-07 Amryt Pharmaceuticals Inc Lomitapida para uso em métodos para tratar hiperlipidemia e hipercolesterolemia em pacientes pediátricos
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
IL324432A (en) 2023-05-24 2026-01-01 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) * 1990-06-18 1994-01-04 E. R. Squibb & Sons, Inc. Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en) 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
KR920014799A (ko) * 1991-01-18 1992-08-25 나오가따 다이도 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제
US5288725A (en) * 1992-10-15 1994-02-22 Merck & Co., Inc. Pyrroloquinoline Bradykinin antagonist
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications

Also Published As

Publication number Publication date
OA11651A (en) 2004-12-07
IS2278B (is) 2007-09-15
SI1114032T1 (uk) 2004-12-31
ID27838A (id) 2001-04-26
HUP0103512A2 (hu) 2002-02-28
HRP20010200A2 (en) 2002-04-30
MA26689A1 (fr) 2004-12-20
NO319781B1 (no) 2005-09-12
BR9913855A (pt) 2001-07-24
BG65101B1 (bg) 2007-02-28
SK3532001A3 (en) 2001-12-03
TNSN99170A1 (fr) 2005-11-10
NZ509837A (en) 2002-11-26
PA8481201A1 (es) 2000-09-29
HK1039938A1 (zh) 2002-05-17
PT1114032E (pt) 2004-09-30
JP3561474B2 (ja) 2004-09-02
PE20001054A1 (es) 2000-10-14
CN1515259A (zh) 2004-07-28
EP1114032B1 (en) 2004-06-02
DZ2891A1 (fr) 2003-12-15
EA005761B1 (ru) 2005-06-30
CA2344248C (en) 2007-01-09
KR20010085814A (ko) 2001-09-07
CU23053A3 (es) 2005-06-24
CN1318057A (zh) 2001-10-17
KR100422286B1 (ko) 2004-03-11
PL346830A1 (en) 2002-02-25
EE200100167A (et) 2002-06-17
HRP20010200B1 (en) 2006-10-31
US6140343A (en) 2000-10-31
AR030523A1 (es) 2003-08-27
YU18101A (sh) 2004-05-12
DK1114032T3 (da) 2004-08-16
WO2000017165A1 (en) 2000-03-30
PL198124B1 (pl) 2008-05-30
GC0000108A (en) 2005-06-29
IS5858A (is) 2001-02-23
JP2002526476A (ja) 2002-08-20
EP1114032A1 (en) 2001-07-11
MY121405A (en) 2006-01-28
AU747715B2 (en) 2002-05-23
AP2001002100A0 (en) 2001-03-31
US6489478B1 (en) 2002-12-03
AU5440399A (en) 2000-04-10
ZA200101745B (en) 2002-05-02
DE69917790D1 (de) 2004-07-08
CZ2001954A3 (cs) 2001-12-12
ATE268324T1 (de) 2004-06-15
AP1345A (en) 2004-12-15
CR6306A (es) 2003-08-28
HUP0103512A3 (en) 2002-03-28
GEP20032973B (en) 2003-05-27
SV1999000150A (es) 2000-06-06
TW502022B (en) 2002-09-11
BG105429A (en) 2001-12-29
NO20011349L (no) 2001-05-14
CA2344248A1 (en) 2000-03-30
ES2221420T3 (es) 2004-12-16
NO20011349D0 (no) 2001-03-16
EA200100249A1 (ru) 2001-08-27
DE69917790T2 (de) 2005-06-09
TR200100780T2 (tr) 2001-07-23
IL141388A0 (en) 2002-03-10
CO5290250A1 (es) 2003-06-27
GT199900147A (es) 1999-09-06

Similar Documents

Publication Publication Date Title
BG105429A (en) 4-amino-substituted-2-substituted-1,2,3,4- tetrahydroquinolines as cetp inhibitors
BG105428A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
MY121838A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
CA2282183A1 (en) Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
BR9904162A (pt) 4-carboxiamino-2-metil-1,2,3,4-tetra-hidroquinolinas aneladas
TW200508222A (en) Quinoline and quinoxaline compounds
UA83202C2 (uk) Фенілзаміщені піперидини для використання як активаторів рапп
NO993096L (no) Orale cyklosporinformuleringer
NZ319090A (en) (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
WO2002020501A3 (en) Polyarylcarboxamides useful as lipid lowering agents
TR199900920T2 (xx) Nafthiridin t�revleri.
AU6894800A (en) Caspase inhibitors and uses thereof
TR200300594T2 (tr) Plazma lipoprotein(a)'yı ve kardiyovasküler hastalıkların risk faktörlerini azaltmak için terkipler ve yöntemler
IL144636A (en) Thioamide derivatives
CA2378834A1 (en) Pyrazinones, compositions containing such compounds
WO2002014313A3 (de) Neue beta-amyloid inhibitoren, verfahren zu deren herstellung und deren verwendung als arzneimittel
TW200616963A (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
WO2001085760A8 (en) Thrombin inhibitors
AP2002002494A0 (en) Hygromycin derivatives.
DK0912568T3 (da) Imidazopyridiner
SE0002354D0 (sv) New formulation
ECSP993134A (es) 1,2,3,4- tetrahidroquinolinas -2 -sustituidas 4- carboxiamino sustituidas
ECSP993135A (es) 1,2,3,4- tetrahidroquinolinas -2 -sustituidas 4- amino sustituidas
CA2244140A1 (en) Alkylated styrenes as prodrugs to cox-2 inhibitors